Pharmacology, Toxicology and Pharmaceutical Science
Dapagliflozin
93%
Placebo
66%
Saxagliptin
53%
Glucose
26%
Hemoglobin A1c
20%
Carbohydrate
13%
Glucosuria
13%
Enalapril Maleate
13%
Cotransporter
13%
Monotherapy
6%
Insulin
6%
Non Insulin Dependent Diabetes Mellitus
6%
Lipid
6%
Fatty Acid
6%
Tritium
6%
Glucagon
6%
Dipeptidyl Peptidase IV Inhibitor
6%
Dapagliflozin Plus Saxagliptin
6%
Fuel
6%
Rose
6%
Medicine and Dentistry
Dapagliflozin
93%
Gluconeogenesis
33%
Glucose
26%
Hemoglobin A1c
20%
Carbohydrate
13%
Lipid Oxidation
13%
Cotransporter
13%
Glucosuria
13%
Enalapril Maleate
13%
Therapeutic Procedure
13%
Plasma
13%
Fatty Acid
6%
Combination Therapy
6%
Glycemic Control
6%
Maturity Onset Diabetes of the Young
6%
Patient with Type 2 Diabetes
6%
Monotherapy
6%
Lipid
6%
Glucose Oxidation
6%
Hormone Determination
6%
Glucagon
6%
Drug Administration
6%
Dipeptidyl Peptidase-4 Inhibitor
6%
Glucose Utilization
6%
Tritium
6%
Urinary System
6%
Patient
6%
Inpatient
6%
Biochemistry, Genetics and Molecular Biology
Dapagliflozin
100%
Gluconeogenesis
33%
Glucose
20%
Alpha Oxidation
20%
Glucose Blood Level
13%
Lipid Oxidation
13%
Cotransporter
13%
Carbohydrate
13%
Excretion
6%
Insulin
6%
Kinetics
6%
Fatty Acid Blood Level
6%
Glucose Oxidation
6%
Glucagon
6%
Glycemic Control
6%
Glucose Utilization
6%
Dipeptidyl Peptidase-4
6%
Reduction (Chemistry)
6%
Glucose Urine Level
6%
Lipid
6%
Rose
6%